ABL Bio Inc
298380
Company Profile
Business description
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
Contact
2nd Floor, 16 Daewangpangyo-Ro 712
Beon-Gil, Bundang-Gu
Gyeonggi-do
Seongnam-si13488
KORT: +82 3180189800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
104
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,723.50 | 17.90 | -0.20% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,213.88 | 42.22 | 0.10% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,530.48 | 292.74 | 1.26% |
| NASDAQ | 19,479.80 | 66.47 | -0.34% |
| Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,974.38 | 6.49 | -0.11% |
| S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
| SSE Composite Index | 3,359.90 | 2.21 | -0.07% |